Market Overview

Jefferies Upgrades Nanosphere to Buy

Related NSPH
8 Biggest Mid-Day Winners
Mid-Morning Market Update: Markets Slightly Higher; Arbor Pharmaceuticals to Buy XenoPort For $7.03/Share

Molecular diagnostics developer Nanosphere (NASDAQ: NSPH) was upgraded from Hold to buy at Jefferies & Company on Tuesday.

Jefferies said in the research report that, "We are upgrading NSPH to Buy (from Hold) on expectations for its recently FDA approved gram-positive blood stream infection test to drive a significant acceleration in new system placements & revenue. We are raising our 2012 & 2013 revenue forecasts to $9.5M (from $9M) and $28M (from $20M), respectively. Our PT moves to $5 (from $2) on higher cash flow forecasts."

Nanosphere reported on June 27 that it had received the FDA authorization to market its Gram-Positive Blood Culture Test, stating that "the BC-GP test notably expands Nanosphere's infectious disease test capabilities to include fast detection of bacteria that can cause deadly bloodstream infections, an increasingly recognized health threat."

“With the BC-GP test, patients suspected of deadly infections can now get a first-ever diagnostic tool for detecting disease-causing bacteria while simultaneously determining antibiotic resistance within the critical timeframe for making and adjusting initial treatment," said William Moffitt, Nanosphere's Chief Executive Officer.

On Tuesday, Nanosphere traded at about $3.20, up roughly 27.8 percent.

Follow me @BCallwood.

Latest Ratings for NSPH

May 2016Rodman & RenshawDowngradesBuyNeutral
Mar 2016Rodman & RenshawInitiates Coverage onBuy
Nov 2015PiperJaffrayMaintainsNeutral

View More Analyst Ratings for NSPH
View the Latest Analyst Ratings

Stock chart: 
Stock chart

Posted-In: Analyst Color News Upgrades Price Target FDA Management Analyst Ratings Movers Best of Benzinga


Related Articles (NSPH)

View Comments and Join the Discussion!